Mainz Biomed (NASDAQ:MYNZ) Raised to Hold at Wall Street Zen

Mainz Biomed (NASDAQ:MYNZ) was upgraded by Wall Street Zen to a “hold” rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings restated a “sell (e)” rating on shares of Mainz Biomed in a report on Monday. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Mainz Biomed presently has an average rating of “Hold” and a consensus target price of $14.00.

Mainz Biomed Price Performance

NASDAQ MYNZ opened at $1.27 on Friday. Mainz Biomed has a one year low of $0.92 and a one year high of $8.20. The stock has a 50-day moving average of $1.25 and a 200 day moving average of $1.51. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.43 and a current ratio of 0.52. The company has a market capitalization of $10.90 million, a price-to-earnings ratio of -0.02 and a beta of 0.27.

Mainz Biomed (NASDAQ:MYNZ) last announced its quarterly earnings results on Friday, September 26th. The company reported ($1.32) earnings per share (EPS) for the quarter. The firm had revenue of $0.14 million for the quarter. On average, sell-side analysts forecast that Mainz Biomed will post -23.6 EPS for the current year.

Hedge Funds Weigh In On Mainz Biomed

A hedge fund recently raised its stake in Mainz Biomed stock. Armistice Capital LLC increased its holdings in Mainz Biomed NV (NASDAQ:MYNZ) by 38.4% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 394,519 shares of the company’s stock after buying an additional 109,519 shares during the quarter. Armistice Capital LLC owned 7.29% of Mainz Biomed worth $588,000 at the end of the most recent reporting period.

About Mainz Biomed

Mainz Biomed AG is a molecular diagnostics company headquartered in Mainz, Germany, specializing in epigenetics-based tests for the early detection of cancer. The company develops proprietary assays that analyze DNA methylation patterns and other epigenetic biomarkers to identify malignancies at a stage when treatment outcomes are most favorable. Mainz Biomed’s technology platform is designed to offer non-invasive, easy-to-use screening solutions that can be deployed both in laboratory settings and at point of care.

The company’s flagship product, ColoAlert®, is a stool-based colorectal cancer screening test that combines DNA methylation markers with bacterial gene targets to improve sensitivity and specificity for detecting advanced adenomas and early-stage colorectal cancer.